Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
144 participants
OBSERVATIONAL
2008-06-30
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Construction and Use of Lung Tumor Microarray for the Analysis of Gene Expression in Lung Cancer
NCT00340847
Biomarker Discovery and Validation in Lung Cancer
NCT01147562
Biomarkers in Tissue and Blood Samples From Patients With Early-Stage Non-Small Cell Lung Cancer
NCT01139944
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
NCT01414595
Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer
NCT00897143
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Surgical removal of the tumor
3. Age between 18 and 75 years
4. Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria
2. Adjuvant treatment with chemotherapy.
3. Prior history of cancer in the past 5 years or breast cancer at any time.
4. Life expectancy less than 3 years in the opinion of the investigator due to concurrent illnesses.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical Prognosis Institute A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steen Knudsen, PhD
Role: STUDY_CHAIR
Medical Prognosis Institute (MPI)
Jens B. Sørensen, MD
Role: STUDY_DIRECTOR
Dept. Oncology, Copenhagen University
Jesper Ravn, MD
Role: STUDY_DIRECTOR
University of Copenhagen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama
Birmingham, Alabama, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Aarhus University Hospital
Aarhus, , Denmark
University of Copenhagen
Copenhagen, , Denmark
Odense University Hospital
Odense, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-B-2007-099
Identifier Type: -
Identifier Source: secondary_id
WIRB Protocol #20080904
Identifier Type: -
Identifier Source: secondary_id
MPI-1001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.